The market for cancer drugs is an ever-roiling mix of
shortages of low-cost generics and glut of high-priced brand pharmaceuticals.
This creates challenges for oncologists and oncology
practices as they try to develop effective treatment plans for patients based
on established drug therapies.
The answer, according to McKesson’s Grant Bogle, senior vice
president, pharmaceutical and biotech solutions, is following treatment
pathways that prioritize the efficacy, safety and cost of treatment regimens
for specific types of cancer.